This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain National Vision (EYE) For Now
by Zacks Equity Research
Investors are optimistic about National Vision's (EYE) better-than-expected earnings and new store growth.
Here's Why Investors Should Retain LabCorp (LH) Stock for Now
by Zacks Equity Research
Investors are optimistic about LabCorp's (LH) robust Drug Development business performance and several pandemic-related developments.
Charles River (CRL) Prospers Internationally Amid FX Headwind
by Zacks Equity Research
Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.
Pfizer (PFE) to Buy 8.1% Stake in Lyme Disease Vaccine Partner
by Zacks Equity Research
Pfizer (PFE) is set to acquire 8.1% stake in Valneva's stock. Valneva will use the cash from this investment to support its phase III study for VLA15.
LabCorp (LH) Gets FDA Nod for VirSeq SARS-CoV-2 NGS Test
by Zacks Equity Research
LabCorp's (LH) VirSeq SARS-CoV-2 NGS Test can detect specific SARS-CoV-2 strains to help health care providers make appropriate patient treatment decisions.
Bruker (BRKR) BSI & BEST Arms Drive Growth Amid Competition
by Zacks Equity Research
Bruker (BRKR) Nano Group's microelectronics and semiconductor metrology tools continue to perform well with ongoing strength in bookings and backlog.
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Crohn's Disease
by Zacks Equity Research
The FDA approval of AbbVie's (ABBV) Skyrizi for moderately to severely active Crohn's disease was supported by data from two phase III induction studies - ADVANCE, MOTIVATE, and one maintenance study - FORTIFY.
Walgreens (WBA) Starts COVID Jabs for 3-Year Olds & Above
by Zacks Equity Research
Walgreens Boots (WBA) continues to serve communities with COVID testing and vaccinations to fight the pandemic.
Here's Why You Should Invest in Bio-Rad (BIO) Stock Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad's (BIO) strong growth in its key product lines across several geographies.
Exelixis (EXEL), BioInvent Tie Up for Immuno-Oncology Therapies
by Zacks Equity Research
Exelixis (EXEL) looks to expand its biotherapeutics development pipeline by using BioInvent's proprietary immuno-oncology screening platform and antibody library.
ObsEva's (OBSV) Yselty Gets EU Nod to Treat Uterine Fibroids
by Zacks Equity Research
ObsEva's (OBSV) Yselty receives its first marketing approval in the European Union for the treatment of uterine fibroids in adult women. Shares were up 11% in pre-market trading following the news.
Valneva (VALN) Stock Declines 59% in 3 Months: Here's Why
by Zacks Equity Research
Though Valneva's (VALN) COVID-19 vaccine looks promising, the European Commission's intent to terminate the advance purchase agreement for the vaccine puts the future of the company's COVID-19 vaccine program into jeopardy.
Henry Schein (HSIC) Global Dental Arm Rebounds Amid Cost Woes
by Zacks Equity Research
Henry Schein's (HSIC) widespread network and channel mix along with favorable long-term trends in the dental business look encouraging.
Rhythm Pharma (RYTM) Down on Mixed Imcivree Regulatory Updates
by Zacks Equity Research
The FDA approves label expansion of Rhythm Pharma's (RYTM) Imcivree to include Bardet-Biedl Syndrome patients. However, the FDA provides CRL for label expansion of the drug in Alstrom syndrome.
Bausch (BHC) Suspends IPO Plans for Solta Medical
by Zacks Equity Research
Bausch (BHC) suspends its plans for the initial public offering of its Solta Medical business in light of the challenging market conditions and other factors.
Hologic (HOLX) New Products Aid Growth, Margin Pressure Stays
by Zacks Equity Research
Hologic's (HOLX) core molecular diagnostics franchise is growing driven by strong uptake in newer assays such as vaginitis panel and menu within the virology product line.
Clovis (CLVS) Up 19.4% on Upbeat Data From Solid Tumor Study
by Zacks Equity Research
Clovis Oncology (CLVS) reports favorable data from a study, which supports the potential clinical utility of FAP-2286, its targeted radiotherapy candidate, as a treatment for advanced solid tumors.
Roche (RHHBY) Alzheimer's Disease Drug Data Disappoints
by Zacks Equity Research
Roche's (RHHBY) study evaluating crenezumab in autosomal dominant Alzheimer's disease did not slow or prevent cognitive decline in people with a specific genetic mutation that causes its early onset.
Bruker (BRKR) Debuts Module on Ultima Multiphoton Microscopes
by Zacks Equity Research
Bruker's (BRKR) NeuraLight 3D Ultra module offers revolutionary 3D holographic photostimulation to support neuroscience and optogenetics research applications.
Boston Scientific (BSX) to Broaden Stent Portfolio With Buyout
by Zacks Equity Research
According to Boston Scientific (BSX), M.I.Tech's product offerings complement the company's existing stent portfolio, including the differentiated AXIOS Stent and Electrocautery Enhanced Delivery System.
Pfizer (PFE) Starts EU Submission of Variant-Adapted Vaccine
by Zacks Equity Research
Pfizer (PFE) and its partner BioNTech initiate rolling submission, seeking authorization of the variant-adapted version of their COVID-19 vaccine.
ResMed (RMD) Inks Deal to Acquire MEDIFOX DAN in Germany
by Zacks Equity Research
ResMed's (RMD) acquisition of a renowned out-of-hospital software solutions company is expected to strengthen its SaaS business.
Here's Why You Should Hold Quest Diagnostics (DGX) Stock Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) owing to a strong recovery in its base business and encouraging 2022 guidance.
Moderna's (MRNA) COVID-19 Vaccine Nears EUA in Pediatrics
by Zacks Equity Research
An FDA advisory committee voted in favor of the use of Moderna's (MRNA) COVID-19 vaccine in individuals aged 6 years to 17 years. A meeting to discuss the use of the vaccine in the younger population is scheduled for today.
Valneva (VALN) Down on its COVID-19 Vaccine Update in Europe
by Zacks Equity Research
Valneva (VALN) slides on a proposed remediation plan update after receiving the European Commission's notice of intent to terminate the Advance Purchase Agreement for its COVID-19 vaccine.